186 related articles for article (PubMed ID: 22819085)
1. Disease activity assessment and patient-reported outcomes in patients with early rheumatoid arthritis.
Sokka T; Rannio T; Khan NA
Rheum Dis Clin North Am; 2012 May; 38(2):299-310. PubMed ID: 22819085
[TBL] [Abstract][Full Text] [Related]
2. How should rheumatoid arthritis disease activity be measured today and in the future in clinical care?
Sokka T
Rheum Dis Clin North Am; 2010 May; 36(2):243-57. PubMed ID: 20510232
[TBL] [Abstract][Full Text] [Related]
3. Tight disease control in early RA.
Sen D; Brasington R
Rheum Dis Clin North Am; 2012 May; 38(2):327-43. PubMed ID: 22819087
[TBL] [Abstract][Full Text] [Related]
4. Magnetic resonance imaging applications in early rheumatoid arthritis diagnosis and management.
Troum OM; Pimienta O; Olech E
Rheum Dis Clin North Am; 2012 May; 38(2):277-97. PubMed ID: 22819084
[TBL] [Abstract][Full Text] [Related]
5. Initial management of rheumatoid arthritis.
Gramling A; O'Dell JR
Rheum Dis Clin North Am; 2012 May; 38(2):311-25. PubMed ID: 22819086
[TBL] [Abstract][Full Text] [Related]
6. Remission in early rheumatoid arthritis -- a comparison of new ACR/EULAR remission criteria to established criteria.
Kuriya B; Sun Y; Boire G; Haraoui B; Hitchon C; Pope JE; Thorne JC; Keystone EC; Bykerk VP;
J Rheumatol; 2012 Jun; 39(6):1155-8. PubMed ID: 22505708
[TBL] [Abstract][Full Text] [Related]
7. Assessment of control of rheumatoid arthritis disease activity.
Salomon-Escoto KI; Gravallese EM; Kay J
Best Pract Res Clin Rheumatol; 2011 Aug; 25(4):497-507. PubMed ID: 22137920
[TBL] [Abstract][Full Text] [Related]
8. Quality of life and the outcome of established rheumatoid arthritis.
Kingsley G; Scott IC; Scott DL
Best Pract Res Clin Rheumatol; 2011 Aug; 25(4):585-606. PubMed ID: 22137926
[TBL] [Abstract][Full Text] [Related]
9. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial.
Svensson B; Boonen A; Albertsson K; van der Heijde D; Keller C; Hafström I
Arthritis Rheum; 2005 Nov; 52(11):3360-70. PubMed ID: 16255010
[TBL] [Abstract][Full Text] [Related]
10. Systematic monitoring of disease activity using an outcome measure improves outcomes in rheumatoid arthritis.
Katchamart W; Bombardier C
J Rheumatol; 2010 Jul; 37(7):1411-5. PubMed ID: 20436069
[TBL] [Abstract][Full Text] [Related]
11. Validity and reliability problems with patient global as a component of the ACR/EULAR remission criteria as used in clinical practice.
Masri KR; Shaver TS; Shahouri SH; Wang S; Anderson JD; Busch RE; Michaud K; Mikuls TR; Caplan L; Wolfe F
J Rheumatol; 2012 Jun; 39(6):1139-45. PubMed ID: 22589262
[TBL] [Abstract][Full Text] [Related]
12. Achieving tight control in rheumatoid arthritis.
van Hulst LT; Hulscher ME; van Riel PL
Rheumatology (Oxford); 2011 Oct; 50(10):1729-31. PubMed ID: 21933791
[No Abstract] [Full Text] [Related]
13. Improving the routine management of rheumatoid arthritis: the value of tight control.
Mease PJ
J Rheumatol; 2010 Aug; 37(8):1570-8. PubMed ID: 20595287
[TBL] [Abstract][Full Text] [Related]
14. Definition of treatment response in rheumatoid arthritis based on the simplified and the clinical disease activity index.
Aletaha D; Martinez-Avila J; Kvien TK; Smolen JS
Ann Rheum Dis; 2012 Jul; 71(7):1190-6. PubMed ID: 22454398
[TBL] [Abstract][Full Text] [Related]
15. A proposed 30-45 minute 4 page standard protocol to evaluate rheumatoid arthritis (SPERA) that includes measures of inflammatory activity, joint damage, and longterm outcomes.
Pincus T; Brooks RH; Callahan LF
J Rheumatol; 1999 Feb; 26(2):473-80. PubMed ID: 9972990
[TBL] [Abstract][Full Text] [Related]
16. Established rheumatoid arthritis: clinical assessments.
van Riel PL; Fransen J
Best Pract Res Clin Rheumatol; 2007 Oct; 21(5):807-25. PubMed ID: 17870029
[TBL] [Abstract][Full Text] [Related]
17. Differences in clinical status measures in different ethnic/racial groups with early rheumatoid arthritis: implications for interpretation of clinical trial data.
Yazici Y; Kautiainen H; Sokka T
J Rheumatol; 2007 Feb; 34(2):311-5. PubMed ID: 17304656
[TBL] [Abstract][Full Text] [Related]
18. Imaging in rheumatoid arthritis.
Tan YK; Conaghan PG
Best Pract Res Clin Rheumatol; 2011 Aug; 25(4):569-84. PubMed ID: 22137925
[TBL] [Abstract][Full Text] [Related]
19. Effects of double filtration plasmapheresis, leflunomide, and methotrexate on inflammatory changes found through magnetic resonance imaging in early rheumatoid arthritis.
Yu X; Wang L; Xu P; Lu W; Lan G; Ping L; Wang X; Tian J; Liu J
J Rheumatol; 2012 Jun; 39(6):1171-8. PubMed ID: 22505700
[TBL] [Abstract][Full Text] [Related]
20. An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the Disease Activity Score (DAS) in a rheumatoid arthritis clinical trial.
Pincus T; Strand V; Koch G; Amara I; Crawford B; Wolfe F; Cohen S; Felson D
Arthritis Rheum; 2003 Mar; 48(3):625-30. PubMed ID: 12632413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
